Unresectable Solid Tumor Clinical Trials

9 recruiting

Unresectable Solid Tumor Trials at a Glance

12 actively recruiting trials for unresectable solid tumor are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Houston, Boston, and San Francisco. Lead sponsors running unresectable solid tumor studies include Xinhua Zhang, MD, M.D. Anderson Cancer Center, and Frontier Medicines Corporation.

Browse unresectable solid tumor trials by phase

Treatments under study

About Unresectable Solid Tumor Clinical Trials

Looking for clinical trials for Unresectable Solid Tumor? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Unresectable Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Unresectable Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Not Applicable

Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

Metastatic CancerUnresectable Solid Tumor
Washington University School of Medicine24 enrolled1 locationNCT05831579
Recruiting
Phase 1

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
Phase 1

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

CholangiocarcinomaAdvanced Solid TumorMetastatic Solid Tumor+1 more
Massachusetts General Hospital70 enrolled1 locationNCT06302621
Recruiting
Not Applicable

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Stage I Colorectal Cancer AJCC v6 and v7Stage II Colorectal Cancer AJCC v7Stage III Colorectal Cancer AJCC v7+45 more
M.D. Anderson Cancer Center590 enrolled1 locationNCT01365169
Recruiting
Phase 1Phase 2

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting
Phase 1Phase 2

A Beta-only IL-2 ImmunoTherapY Study

Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Unresectable Solid TumorGastrointestinal Stromal TumorsRecurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD74 enrolled1 locationNCT05461664
Recruiting

A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors

Unresectable Solid TumorGastrointestinal Stromal TumorsRecurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD74 enrolled1 locationNCT05464875
Recruiting
Phase 1

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid TumorAdvanced Unresectable Solid Tumor
TopAlliance Biosciences499 enrolled24 locationsNCT04137900